NEUROCRINE BIOSCIENCES INC

Neurocrine CMO Roberts Eiry’s 51k‑share stake signals deep insider confidence—insight on options, RSUs, and what it means for investors and the company’s future.

Neurocrine insider trades reveal exec confidence and disciplined liquidity—stable equity holdings, robust R&D and a mid‑cap biotech outlook.

Insider buying at Neurocrine Biosciences signals strong confidence in its neurodegenerative pipeline – what does this mean for investors?

Neurocrine insider action: CCO Eric Benevich buys shares at $43.24, below market, signaling confidence in neuropsychiatric pipeline and potential upside.